At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Merck & Co., Inc. MRK announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion recommending marketing ...
The Food and Drug Administration approved Keytruda plus chemotherapy, followed by single-agent Keytruda for primary advanced or recurrent endometrial cancer. The Food and Drug Administration (FDA) ...
KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback